Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report)’s share price hit a new 52-week high on Wednesday . The stock traded as high as $77.40 and last traded at $77.40, with a volume of 100 shares. The stock had previously closed at $64.70.
Basilea Pharmaceutica Stock Up 18.2%
The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59. The stock has a 50 day simple moving average of $61.48 and a 200-day simple moving average of $66.67.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
- Why Lowe’s Could Be a Bargain Before Housing Recovers
- Okta’s AI Tailwind Could Put This Forgotten Software Stock Back in Play
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
-sa-logo-1200x675.png){kind=logo}
